Contributors to Pharmacotherapy: A Pathophysiologic Approach must disclose relevant financial and other interests with entities that produce, market, sell, or distribute medications, health products, or services related to the medication use process. All contributors will complete, sign, and submit a conflict of interest (COI) disclosure statement to the Editors. Starting with the 11th edition, the COI disclosure must be submitted after an invitation has been extended and before a contributor agreement is signed.
After reviewing the COI disclosure statement submitted by a contributor, the Editors will develop and approve a plan to mitigate any and all potential COI's that might be reasonably perceived by the readers of Pharmacotherapy: A Pathophysiologic Approach to unduly influence the contributor's favorable or unfavorable portrayal of any product or service. The mitigation plan may include, but is not limited to, assigning a coauthor with no COI's to work with the contributor, subjecting the contribution to external peer review, or asking the contributor to divest the interest(s).
No contributor may receive a payment or services from a third party (commercial entity, government agency, professional organization, private foundation, etc.) for any work product submitted to Pharmacotherapy: A Pathophysiologic Approach. Starting with the 11th edition, potential contributors who are employees of a commercial entity that produces, markets, sells, or distributes medications or healthcare products generally will not be invited or re-invited to contribute.
COI disclosures for all contributors to Pharmacotherapy: A Pathophysiologic Approach will be made available to readers online. The internet address for the COI disclosure page will be published in the Contributors section of the text.